SITE Centers Corp.

SITE Centers Corp.

0.71
USD
+0.05
(+8.03%)
2.45EPS
1.37P/E
176.84MMarket Cap
Feb 17Next Earn
SITE Centers Corp.
NYSE:SITC
(New York Stock Exchange)

Recent

price

0.71

P/E

ratio

1.37

div

yld

282.94%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
24.25
21.13
19.71
20.34
22.02
22.79
22.03
19.88
15.18
11.08
9.52
10.25
9
8.64
5.3
2.36
1
Revenue per Share
-8.23
-1.4
-1.52
-0.93
2.08
-2.1
0.82
-5.89
1.75
1.5
0.31
2.14
2.96
4.86
9.97
3.39
2.45
Basic EPS, GAAP
3.72
1.64
8.48
9.17
9.39
9.61
10.09
8.94
5.71
5.9
3.93
5.43
4.83
4.56
2.14
0.37
-0.55
Free Cash Flow per Basic Share
2.01
2.24
4.31
4.77
5.37
5.88
6.44
6.66
6.1
3.95
2.03
1.91
2.25
2.3
2.44
6.78
2.01
Dividend per Share
79.56
62.49
61.86
74.47
72.51
65.04
63.23
51.37
34.08
34.18
33.49
35.3
36.31
38.28
9.9
6.38
5.28
Book Value per Share
79.56
61.38
59.13
65.75
64.26
58.52
57.94
47.41
32.37
32.98
31.61
33.51
34.65
37.62
9.65
6.24
5.28
Tangible Book Value per Share
31
34
36
41
45
45
46
46
46
46
48
52
53
52
52
52
52
Basic Weighted Avg Shares
742
714
707
830
986
1,028
1,006
913
700
507
460
533
479
453
277
124
53
Sales/Revenue/Turnover
31.19
29.24
28.64
25.86
22.04
25.19
26.16
24.76
26.93
28.39
21.37
26.13
21.08
17.09
12.03
-1.26
-46.92
Operating Margin (%)
227
230
251
324
419
402
390
346
242
165
171
186
204
212
131
45
19
Depreciation Expense
-209
-16
-26
-10
117
-72
60
-242
114
101
36
125
169
266
532
178
129
Net Income, GAAP
- -
- -
3.86
11.14
8.08
- -
2.83
- -
0.74
0.64
3
1.22
0.58
0.88
0.14
- -
- -
Effective Tax Rate (%)
-28.22
-2.22
-3.65
-1.23
11.9
-7.02
5.97
-26.47
16.34
19.86
7.76
23.45
35.21
58.7
191.67
143.84
244.03
Profit Margin (%)
-19
14
-97
-120
-266
-253
-215
-126
-139
-167
-71
-131
-142
1,291
-14
58
204
Working Capital
4,302
4,105
4,319
5,295
5,212
5,140
4,494
3,849
1,884
1,847
1,934
1,677
1,707
1,601
301
- -
- -
LT Debt
3,135
3,078
3,366
3,928
3,798
3,463
3,246
2,897
2,073
1,981
1,945
2,043
2,093
2,176
517
335
277
Total Equity
- -
- -
2.46
2.23
2.47
- -
1.81
- -
2.3
3.56
3.43
3.86
3.74
2.1
-3.24
- -
- -
Return on Invested Capital (%)
- -
- -
2.16
2.1
3.71
- -
3.27
- -
4.68
4.66
2.81
5.17
6.5
9.12
25.74
- -
- -
Return on Capital (%)
-10.38
-1.82
-1.94
-1.18
2.69
-2.9
1.26
-10.3
4.14
4.28
0.93
6.4
8.35
13.01
41.49
41.78
43.96
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
52
52
52
Market Capitalization
283
208
177

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
214
254
227
Cash, Cash Equivalents & STI
193
239
200
Accounts Receivable, Net
11
8
7
Inventories
- -
- -
- -
Total Current Liabilities
66
83
23
Payables & Accruals
66
83
22
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-15.18%
-20.01%
-35.22%
Free Cash Flow
-17.07%
-20.64%
-82.5%
Net Income, GAAP
-53.39%
75.18%
-66.56%
Sales/Revenue/Turnover
-16.55%
-18.8%
-55.44%
Total Cash Common Dividend
16.18%
49.25%
200.39%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
94
88
61
-51
277
2025
43
33
27
20
124
2026
13
11
9
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.5
4.49
6.11
-0.14
9.97
2025
0.06
0.89
-0.12
2.56
3.39
2026
0.02
-0.02
-0.1
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.22
0.58
0.58
0.08
2.44
2025
- -
- -
4.77
2.01
6.78
2026
- -
- -
- -
- -
- -
Business
SITE Centers Corp. (NYSE: SITC) owns, acquires, develops, leases, manages and operates open-air shopping centers primarily located in affluent suburban communities across major U.S. metropolitan statistical areas; its portfolio features grocery-anchored properties, convenience retail centers and community shopping hubs that serve essential retailers including national chains, restaurants, service providers and local tenants, with core services encompassing comprehensive property management, leasing, maintenance, redevelopment, rent collection and marketing to maximize asset value and occupancy. Founded in 1965 as Developers Diversified Realty Inc. by Bert Wolstein and headquartered in Beachwood, Ohio, the self-administered real estate investment trust generates revenue mainly from rental income and management fees, targeting high-income trade areas that emphasize convenience, last-mile accessibility and sustainable community retail experiences in regions such as the Northeast, Southeast, Midwest and Texas. Recent strategic changes include aggressive capital recycling through over $1 billion in dispositions since mid-2023, such as the November 2025 sales of four properties including Paradise Village Gateway and Parker Pavilions, alongside acquisitions of premium convenience assets like Crocker Commons in Cleveland and Maple Corner in Nashville during 2024; the company continues selective divestitures of non-core holdings like East Hanover Plaza and Edgewater Towne Center while pursuing special common stock distributions and portfolio optimization announced in 2025 earnings releases.

Company News

  • Werewolf Therapeutics' Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting

  • GT Biopharma Oral Presentation at the SITC 2026 Annual Meeting

  • Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer

  • Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026

  • MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)

  • Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting

  • Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)

  • IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer

  • Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio

  • Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026

  • BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

  • BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026

  • MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy

  • SITE Centers Reports Third Quarter 2026 Results

  • Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting

  • Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer

  • Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting

  • GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting

  • Pine Tree Acquires Sponsor Interest in a 10-Property, $644M Shopping Center Portfolio

  • SITE Centers Announces Sale of DTP Interests and Special Common Distribution